Humacyte, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | — | — | — |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$84.6M | -$81.2M |
| Operating expenses | — | $114.4M | $100.0M | $86.1M | $82.5M |
| Cost of revenue | $9.7M | $0 | — | — | — |
| Cash from operations | -$105.0M | -$98.1M | -$73.3M | -$71.1M | -$81.2M |
| Capital expenditure | $884,000 | $1.6M | $2.3M | $1.0M | $220,000 |
| Free cash flow | -$105.9M | -$99.7M | -$75.6M | -$72.2M | -$81.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $116.4M | $137.9M | $128.2M | $204.3M | $286.5M |
| Total liabilities | $113.3M | $190.5M | $114.7M | $87.4M | $164.4M |
| Total debt | — | — | — | $30.0M | — |
Shares outstanding 222.0M · Free float 84.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.